Description
ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA selectively acts at host cell late endosomes rather than targeting toxin or pathogen itself. ABMA has broad-spectrum anti-infection activityIn VitroABMA protects cells against four bacterial toxins ( Corynebacterium diphtheriae (DT; EC 50 of 62.9 µM), Bacillus anthracis (LT), Clostridium difficile toxin B (TcdB; EC 50 of 73.3 µM), Clostridium sordellii lethal toxin (TcsL; EC 50 of 86.7 µM)), three viruses (Ebola (EC 50 of 3.3 µM), rabies (EC 50 of 19.4 µM), dengue-4 virus ( EC 50 of 8.2 µM)), two species of Chlamydiales intracellular bacteria ( Simkania negevensis and Chlamydia trachomatis ), and the parasite Leishmania infantum (EC 50 of 7.1 µM) at micromolar level. In A549 cells, ABMA treatment induces a decrease in ricin cytotoxicity with an EC 50 of 3.8 µM, and a protection factor (R) at 30 µM ranging from 5 to 10. ABMA retained almost 100% of its biological activity against ricin-induced cytotoxicity up to six days. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoABMA (2-200 mg/kg; intraperitoneal injection; female BALB/c mice) treatment protects mice from nasal instillation of an LD 90 of ricin. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Pathogen-free female BALB/c mice (6 week-old) with ricin Dosage: 2 mg/kg, 20 mg/kg, 200 mg/kg Administration: Intraperitoneal injection Result: A statistically significant protection according to survival curves was observed with a single ip dose of 2 mg/kg. The 20 mg/kg dose fully protected animals through to day 21. The 200 mg/kg dose resulted in 80% of protection of mice against ricin challenge with a single animal succumbing on day 15.Form:SolidIC50& Target:Intracellular bacteria, Viruses, Parasite